Search 

There is a high unmet need for central nervous system (CNS) diseases in the growing aging population. Chronic inflammation is associated with a broad spectrum of neurodegenerative diseases related to aging. Genervon is bringing GM6, a new clinical-stage drug asset, to regulatory approval and commercialization in China for CNS diseases including Parkinson’s disease (PD), Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), Multiple Sclerosis (MS), and other neurodegenerative diseases. Most clinical trials for drugs developed through the traditional single-target drug approach have failed to treat the complex neurological disorders that involve multiple interrelated pathways.

GM6 is an innovative first-in-class regulator peptide drug in clinical stage. Genervon Biopharmaceuticals discovered an endogenous embryonic-stage regulator, Motoneuronotrophic Factor (MNTF), and developed from it the pleiotropic drug GM6. GM6 is neither an antibody nor a single-target agonist or antagonist. It is a multi-target regulator which simultaneously acts upon multiple extracellular receptors to modulate a series of signaling pathways mediating inflammation and pro-survival responses in both CNS and immune system. Genervon has validated GM6’s target engagement of multiple targets and druggability. GM6 has been de-risked for toxicity in animal studies and safety in three clinical trials. IND documents filed with the FDA can be used to support regulatory filing in China for clinical trials. Genervon is interested to partner through licensing or merger and acquisition. A complete CMC package is ready for technology transfer.

Jemincare is a leading pharmaceutical group in China with $5.2B revenue in 2019. JeminCare is dedicated to providing novel healthcare solutions with Rx and OTC drugs with strategic fields in renal disease, oncology, cardiovascular, anti-infection, respiratory, and analgesic. We have a well-established marketing and sales network in China with a team of more than 5000 sales reps.

Located in Shanghai, Jemincare R&D center has 400+ experienced scientists and more than 30 novel prescription drugs in the pipeline.

Mira Life Science Ventures was established to change the paradigm for investment, incubation and development of new disruptive and game-changing technologies in the life sciences. Mira LSV will invest in medical devices, therapeutics, diagnostics, enabling technologies and digital healthcare. Mira LSV will focus its efforts in areas of significant unmet medical needs such as cancer, neurological diseases, infectious disease, autoimmune disease, inflammatory diseases, personalized medicine, cardiovascular disease and renal diseases.

In order to change the venture investment paradigm, Mira LSV was formed to break out of the traditional venture model and move to a more flexible, nimble and shareholder-centric model to accelerate development of these break-through products and technologies and bring them to patients. Mira LSV’s highly flexible business structure, broad and diverse access to deal-flow and highly experienced management team will ensure we have a significant positive impact on our healthcare system.